Neogenomics Inc. [NEO] stock is trading at $17.17, down -1.89%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NEO shares have gain 15.39% over the last week, with a monthly amount glided 25.05%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, BTIG Research reaffirmed its Buy rating on December 29, 2023, and dropped its price target to $21. On August 21, 2023, upgrade upgraded it’s rating to Overweight but maintained its price target of $18 on the stock. Raymond James downgraded its rating to a Mkt Perform. BTIG Research upgraded its rating to a Buy but $25 remained the price target by the analyst firm on May 09, 2023. The Benchmark Company upgraded its rating to Buy for this stock on February 24, 2023, but kept the price target unchanged to $20. In a note dated February 01, 2023, Needham upgraded an Buy rating on this stock but restated the target price of $15.
Neogenomics Inc. [NEO] stock has fluctuated between $11.03 and $21.22 over the past year. Currently, Wall Street analysts expect the stock to reach $23 within the next 12 months. Neogenomics Inc. [NASDAQ: NEO] shares were valued at $17.17 at the most recent close of the market. An investor can expect a potential return of 33.95% based on the average NEO price forecast.
Analyzing the NEO fundamentals
Neogenomics Inc. [NASDAQ:NEO] reported sales of 628.25M for the trailing twelve months, which represents a growth of 11.97%. Gross Profit Margin for this corporation currently stands at 0.42% with Operating Profit Margin at -0.15%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.08 and Total Capital is -0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.68 points at the first support level, and at 16.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.47, and for the 2nd resistance point, it is at 17.77.
Ratios To Look Out For
For context, Neogenomics Inc.’s Current Ratio is 2.01. As well, the Quick Ratio is 1.93, while the Cash Ratio is 1.22. Considering the valuation of this stock, the price to sales ratio is 3.50, the price to book ratio is 2.40.
Transactions by insiders
Recent insider trading involved Olivo Alicia C, General Counsel, that happened on May 15 ’24 when 1049.0 shares were sold. Director, TETRAULT LYNN A. completed a deal on Mar 04 ’24 to sell 6112.0 shares. Meanwhile, General Counsel Olivo Alicia C sold 2587.0 shares on Feb 15 ’24.
